Dirk Hondmann PhD joins PeterBio as CEO

PeterBio is excited to announce that Dirk Hondmann has joined the company as CEO.

July 01, 2020

Dirk Hondmann has joined PeterBio as CEO as per July 1st, 2020. Dirk holds a MSc in Molecular Sciences from Wageningen University and a PhD in Molecular Genetics from Groningen University.

Dirk had various R&D and innovation leaderships positions at Unilever and Mead Johnson. At Mead Johnson, he was Chief Scientific Officer and Member of the Executive Leadership team. After the acquisition of Mead Johnson by Reckitt Benkiser, he was instrumental integrating Mead Johnson in Reckitt Benkiser. As Chief Scientific Officer Dirk held a number of adjunct faculty positions, including Medical and Molecular Genetics at Indiana University School of Medicine and at the Department of Pediatric Gastroenterology at Boston’s Children’s Hospital.

“I am very excited to join PeterBio. PeterBio is a young and truly innovative company and after a career with leading global companies I am eager to join a start up that has developed a very promising new gene-editing technology. I am fascinated by the potential this new technology has, and eager to contribute to the further development of PeterBio.” says Dirk Hondmann.

“Dirk will be able to strongly contribute to the further development and commercialization of our proprietary RITDM™ gene-editing technology, as well as innovative cell engineering technologies we are developing.” says Chenzhong Kuang, CSO.

“Dirk brings a wealth of experience. He has deep domain knowledge in molecular biology and a strong background in R&D, business development and corporate management. We are very confident that Dirk will accelerate the development of our RITDM™ technology and PeterBio.” says George Westerkamp, Chairman of the Board.

We use cookies to personalize our service and to improve your experience on the website. We also use thus information for analytics.